Brookwood Investment Group LLC Invests $640,000 in Boston Scientific Corporation $BSX

Brookwood Investment Group LLC acquired a new position in Boston Scientific Corporation (NYSE:BSX) in the 2nd quarter, HoldingsChannel.com reports. The institutional investor acquired 5,954 shares of the medical equipment provider’s stock, valued at approximately $640,000.

Several other hedge funds have also recently made changes to their positions in BSX. 1248 Management LLC bought a new position in shares of Boston Scientific in the 1st quarter worth about $26,000. Y.D. More Investments Ltd bought a new position in shares of Boston Scientific in the 1st quarter worth about $27,000. Sound Income Strategies LLC raised its position in shares of Boston Scientific by 90.9% in the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Princeton Global Asset Management LLC bought a new stake in Boston Scientific in the 2nd quarter valued at about $32,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in Boston Scientific during the 2nd quarter worth approximately $37,000. 89.07% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, EVP Joseph Michael Fitzgerald sold 50,000 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $5,231,500.00. Following the transaction, the executive vice president owned 178,342 shares in the company, valued at $18,659,923.46. The trade was a 21.90% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction that occurred on Friday, August 1st. The stock was sold at an average price of $104.63, for a total value of $1,811,459.19. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,469,268. The trade was a 42.32% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 167,313 shares of company stock worth $17,237,959 in the last 90 days. Company insiders own 0.50% of the company’s stock.

Analyst Ratings Changes

BSX has been the subject of a number of research reports. Truist Financial raised their price objective on Boston Scientific from $129.00 to $130.00 and gave the company a “buy” rating in a research note on Thursday, October 23rd. The Goldman Sachs Group reissued a “buy” rating and issued a $124.00 price objective on shares of Boston Scientific in a research note on Wednesday, October 22nd. Morgan Stanley raised their price objective on Boston Scientific from $125.00 to $130.00 and gave the company an “overweight” rating in a research note on Thursday. Wall Street Zen raised Boston Scientific from a “hold” rating to a “buy” rating in a research note on Saturday, October 11th. Finally, Evercore ISI reissued an “outperform” rating on shares of Boston Scientific in a research note on Wednesday, October 22nd. Two investment analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $123.77.

Boston Scientific Stock Performance

Shares of BSX opened at $102.43 on Tuesday. The company has a debt-to-equity ratio of 0.49, a quick ratio of 0.82 and a current ratio of 1.37. The stock has a 50 day moving average price of $101.13 and a two-hundred day moving average price of $102.16. The firm has a market capitalization of $151.77 billion, a P/E ratio of 54.77, a P/E/G ratio of 2.04 and a beta of 0.61. Boston Scientific Corporation has a 52 week low of $80.64 and a 52 week high of $109.50.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings data on Wednesday, October 22nd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion during the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.74% and a net margin of 14.43%.The company’s revenue for the quarter was up 20.3% on a year-over-year basis. During the same period in the previous year, the company posted $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS. Q4 2025 guidance at 0.770-0.790 EPS. Equities analysts forecast that Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.